Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.

Cancer letters - 1 Oct 2017

Tong Christy W S, Wu William K K, Loong Herbert H F, Cho William C S, To Kenneth K W

Abstract excerpt

The discovery of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) has led to unprecedented clinical response in a subset of lung cancer patients carrying the sensitizing EGFR mutations (L858R or exon 19 deletion). However, disease progression invariably occurs within a year after the initial TKI treatment, predominantly due to the development of acquired resistance caused by the secondary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 28774798
DOI: 10.1016/j.canlet.2017.07.023

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.PMID 28774798Read ↗

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?Semantic proximity Read ↗

The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC.Semantic proximity Read ↗

Emerging treatment for advanced lung cancer with EGFR mutation.Semantic proximity Read ↗

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.Semantic proximity Read ↗

Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?Semantic proximity Read ↗

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical TreatmentSemantic proximity Read ↗

Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.Semantic proximity Read ↗

Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.Semantic proximity Read ↗

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.Semantic proximity Read ↗

Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer.Semantic proximity Read ↗

Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.Semantic proximity Read ↗

Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.